EMA Authorised: Ocrevus (ocrelizumab) — Roche Registration GmbH

View source ↗

Summary

EMA has authorised Ocrevus (ocrelizumab) by Roche Registration GmbH for therapeutic use in multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ocrevus (ocrelizumab)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis. MAH: Roche Registration GmbH. Decision date: 02/07/2026